# Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

- URL: https://talkfuse.com/story/moderna-raises-2026-outlook-as-ceo-says-newer-vaccines-are-gaining-traction/
- Published: 2026-11-06T12:14:24+00:00
- Updated: 2026-11-06T12:22:17+00:00
- Original publisher: CNBC (publisher lean: Centre)
- Original article: https://www.cnbc.com/2026/11/06/moderna-mrna-earnings-q3-2026.html
- Topics: Business, Companies, Health, Medicine

## Key points

- Moderna lifted its 2026 revenue growth forecast to 15% to 25%.
- Third-quarter revenue rose 29% to $1.31 billion.
- Newer vaccines and international sales helped boost results.

## Summary

Moderna reported third-quarter revenue and earnings above analyst expectations and raised its 2026 revenue growth forecast to 15% to 25%, from guidance of up to 10%. The company said newer products and broader international sales helped drive the results, as it seeks to diversify beyond its established Covid vaccine business.

Revenue rose 29% to $1.31 billion, including $780 million in the US and $533 million internationally. Moderna recorded net income of $162 million, or 38 cents per share, compared with a $200 million loss a year earlier. Its next-generation Covid vaccine is contributing for a full year, while the recently approved flu shot is expected to have a limited US launch in 2026; investors are also watching its experimental cancer vaccine with Merck.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.